Clinical Trials Browser

Injections, Subcutaneous × Plasma cell × 30 days × Clear all

NCT07623798 2026-06-03

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Phase 3 Not yet recruiting

Multiple Myeloma, Recurrence